Inflammatory Bowel Disease, Psoriasis May Be Causally Related
THURSDAY, Sept. 22, 2022 -- Inflammatory bowel disease (IBD) appears to have a causal impact on psoriasis, especially psoriatic arthritis (PsA), and total psoriasis and PsA are associated with Crohn disease (CD), according to a study recently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 22, 2022 Category: Pharmaceuticals Source Type: news

Psoriasis Patients Find Psoriatic Arthritis Screening Worthwhile
TUESDAY, Sept. 20, 2022 -- Psoriatic arthritis (PsA) screening is acceptable to patients with psoriasis whether they are diagnosed with PsA or not, according to a research letter published online Aug. 17 in the British Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2022 Category: Pharmaceuticals Source Type: news

S2 Episode 4: Cardiovascular Risk in Patients With Psoriatic Arthritis S2 Episode 4: Cardiovascular Risk in Patients With Psoriatic Arthritis
Drs Stanley Cohen and Atul Deodhar discuss cardiovascular risk in patients with psoriatic arthritis and the impact of effective treatment.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news

Causal Effect ID'd for IBD With Psoriasis, Psoriatic Arthritis
WEDNESDAY, Sept. 14, 2022 -- There seems to be a causal effect between inflammatory bowel disease and psoriasis and psoriatic arthritis, according to a study published online Sept. 14 in JAMA Dermatology. Dennis Freuer, Ph.D., from the University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2022 Category: Pharmaceuticals Source Type: news

Differentiating Axial Disease in PsA Versus AS With Psoriasis Differentiating Axial Disease in PsA Versus AS With Psoriasis
Some identifiers of patients with isolated axial psoriatic arthritis were older age at diagnosis, psoriatic nail lesions, and absence of inflammatory back pain.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 9, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news

TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Outcomes of Drug Therapy in Patients With Psoriatic Arthritis Axial Disease
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 24, 2022 Category: Orthopaedics Tags: CME Article Source Type: news

S2 Episode 3: Treating Psoriatic Arthritis With Methotrexate and csDMARDs S2 Episode 3: Treating Psoriatic Arthritis With Methotrexate and csDMARDs
Drs Stanley Cohen and Caylib Durand discuss the treatment paradigm for psoriatic arthritis and the role of methotrexate and other conventional synthetic disease-modifying antirheumatic drugs.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news

Ustekinumab Becomes Second Biologic Approved for PsA in Kids Ustekinumab Becomes Second Biologic Approved for PsA in Kids
The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to severe plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 2, 2022 Category: Dermatology Tags: Rheumatology News Alert Source Type: news

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Stelara (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, Stelara provides a new therapeutic option for children six years of age and older living with active psoriatic arthritis Active psoriatic arthritis in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2022 Category: Drugs & Pharmacology Source Type: news

S2 Episode 2: How to Optimize Shared Decision-Making in Psoriatic Arthritis S2 Episode 2: How to Optimize Shared Decision-Making in Psoriatic Arthritis
Drs Stanley Cohen and Eric Ruderman dig into three challenging case studies to discuss shared decision-making strategies in the treatment and management of psoriatic arthritis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news

S2 Episode 1: Psoriatic Arthritis and Disease Activity Measures S2 Episode 1: Psoriatic Arthritis and Disease Activity Measures
Drs Stanley Cohen and Alexis Ogdie-Beatty discuss minimal disease activity and the disease activity measures used in clinical trials as well as practice in treating psoriatic arthritis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news

Johnson & Johnson Reports Q2 2022 Results
New Brunswick, N.J. (July 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”OVERALL FINANCIAL RESULTS expand ...
Source: Johnson and Johnson - July 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Novel PsA Treatment Choice Algorithm Uses T-Cell Behavior Novel PsA Treatment Choice Algorithm Uses T-Cell Behavior
A novel treatment algorithm for psoriatic arthritis (PsA) is being developed to provide more precise biologic choices.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news